Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Chief Executive Albert Bourla says he is hopeful about finding a solution in response to Trump’s demand for price cuts.

PFIZER said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting higher-than-expected second-quarter earnings on Tuesday.

Bourla, who took over as CEO in 2019, has declined to say how long he intends to remain in his role at Pfizer. Developing a ...

Pharmaceutical major recorded a revenue jump to $14.65 billion, exceeding the market expectations. The company also raised ...

The tariff threat come just a few days after the White House sent letters to major drugmakers demanding slashed prices for US ...

Pfizer is starting to execute on its turnaround plan and drug pipeline. 10 stocks we like better than Pfizer › Shares of the ...

Shares in the data-software company were up 7.8% Tuesday after it posted higher quarterly results and [boosted its annual ...

Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...

XAU/USD consolidates above the 50-day MA, as softer U.S. data boosts rate cut odds. Gold price future hinges on inflation and ...

Hims & Hers Health posted an increase in profit and revenue for the second quarter on growth in subscribers using personalized treatment plans. The telehealth-consultation platform on Monday posted a ...

Litecoin (LTC) has surged to $119.30 after breaking key resistance at $116, fueled by record transaction volumes and growing ...